Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
Schizophr Res. 2024 Jul 12;271:9-18. doi: 10.1016/j.schres.2024.06.047. Online ahead of print.
ABSTRACT
Schizophrenia is a serious mental disorder, and monitoring remission is a widely used measure of effectiveness of the treatment provided. It is very important to identify possible factors correlating with remission. In our substudy of BeSt InTro, a randomized controlled trial of three antipsychotic drugs, 126 patients with ICD-10 diagnoses F20-29 (F23 excluded) were randomized to one of the second-generation antipsychotic drugs amisulpride, aripiprazole or olanzapine. Remission rate was calculated at seven assessment points, with and without using the time criterion of six months included in the consensus remission criteria. Because of drop-out (n = 77), we had data for 49 patients at one-year follow-up. These data were used to calculate the one-year remission rate to 55 % (27/49), without taking into consideration the 6-month time criterion. When we applied the consensus remission criteria with the 6-month time criterion included, the one-year remission rate was calculated for 59 patients: 29 % (17/59). Antipsychotic drug naivety and low negative symptom load at baseline correlated highly with belonging to the remission group. Use of amisulpride was more probable to lead to remission than that of aripiprazole, but it was not more probable than the use of olanzapine (in per-protocol analyses). Negative symptoms showed the largest resistance to treatment. The lack of remission for the majority of the participants in this closely monitored antipsychotic drug trial is alarming and could act as a reminder that novel treatment principles are needed, especially targeted towards the negative symptoms in schizophrenia.
PMID:39002529 | DOI:10.1016/j.schres.2024.06.047
![Google](https://www.google.com/images/branding/googlelogo/2x/googlelogo_light_color_92x30dp.png)
![Google Keep](https://www.gstatic.com/images/branding/product/1x/keep_48dp.png)
![Share on Linkedin](https://psychiatryai.com/wp-content/uploads/2023/10/linkedin-logo-png-2048-1.png)
Estimated reading time: 5 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Cool Evidence: Engaging Young People and Students in Real-World Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Real-Time Evidence Search [Psychiatry]
![](/wp-content/uploads/2024/04/pubmed.png)
AI Research
![](/wp-content/uploads/2024/05/Il5nR_nf_400x400-modified-1.png)
Remission in schizophrenia spectrum disorders: A randomized trial of amisulpride, aripiprazole and olanzapine
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
Comparative Effectiveness of Amisulpride and Clozapine in the Treatment of Schizophrenia: A Systematic Review and Meta-Analysis Lower plasma tumor necrosis factor-alpha is associated with symptomatic remission in patients with schizophrenia Lower plasma tumor necrosis factor-alpha is associated with symptomatic remission in patients with schizophrenia Assessing Psychological Remission in Adolescent Anorexia Nervosa: A Comparison of Patient and Parent Report Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis Behind the heterogeneity in the long-term course of first-episode psychosis: Different psychotic symptom trajectories are associated with different patterns of cannabis and stimulant use The association between symptomatic remission and social support in community-dwelling schizophrenia patients during COVID-19 The association between symptomatic remission and social support in community-dwelling schizophrenia patients during COVID-19 Effects of atypical antipsychotics on serum asprosin level and other metabolic parameters in patients with schizophrenia Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease Amisulpride as the antipsychotic of choice in severe psychotic disorder with comorbid impaired glucose tolerance Employment, education or training status (NEET) at baseline predicts high-threshold symptomatic remission in first episode psychosis: A cohort study Continuation or maintenance ECT for schizophrenia: A narrative review of case report data Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol Evaluation of inflammatory markers obtained from complete blood count in different stages of schizophrenia Evaluation of inflammatory markers obtained from complete blood count in different stages of schizophrenia Evaluation of inflammatory markers obtained from complete blood count in different stages of schizophrenia Cost-Effectiveness of Digital Mental Health Versus Usual Care During Humanitarian Crises in Lebanon: Pragmatic Randomized Trial Cost-Effectiveness of Digital Mental Health Versus Usual Care During Humanitarian Crises in Lebanon: Pragmatic Randomized Trial Efficacy, acceptability and tolerability of second-generation antipsychotics for behavioural and psychological symptoms of dementia: a systematic review and network meta-analysis Efficacy, acceptability and tolerability of second-generation antipsychotics for behavioural and psychological symptoms of dementia: a systematic review and network meta-analysis Evaluating psychological distress associated with life events under the traumatic experience threshold in patients with major depressive and bipolar disorder Diagnosis and treatment depression in schizophrenia Comparative physiological effects of antipsychotic drugs in children and young people: a network meta-analysis Comorbidity of depression and posttraumatic stress disorder: Outcomes from a randomized controlled trial of surf and hike therapies among service members Olanzapine-induced cardiomyopathy: A mimicker of obesity cardiomyopathy? Infantile Epileptic Spasms Syndrome Complicated by Leigh Syndrome and Leigh-Like Syndrome: A Retrospective, Nationwide, Multicenter Case Series Effects of Actissist, a digital health intervention for early psychosis: A randomized clinical trial Effectiveness of Unguided Internet-Based Cognitive Behavioral Therapy for Subthreshold Social Anxiety Disorder in Adolescents and Young Adults: Multicenter Randomized Controlled Trial Evaluation des Troubles Cognitifs Chez des Patients Tunisiens Atteints de Trouble Bipolaire en Rémission : Étude Cas-Témoins: Assessment of Cognitive Impairment in Tunisian Patients With Bipolar Disorder in Remission: A Case-Control Study Efficacy of acupuncture treatment for breast cancer-related insomnia: study protocol for a multicenter randomized controlled trial Cost-Utility Analysis of Antipsychotic Reduction and Discontinuation in Patients with Long-term Schizophrenia and Psychosis in English Mental Health Trusts: The RADAR Study A Pilot Study of High-Frequency Transcranial Magnetic Stimulation for Bipolar Depression Individual Burden of Illness Index in Bipolar Disorder Remission: A Cross-Sectional Study Three-Year Outcomes of 6-Month Paliperidone Palmitate in Adults With Schizophrenia: An Open-Label Extension Study of a Randomized Clinical Trial Effect of DNA methylation and AUDIT-C polygenic scores on alcohol use disorder comorbidity in psychoses: No evidence of epigenetic basis of polygenic risk Role of different omics data in the diagnosis of schizophrenia disorder: A machine learning study Clinical, cognitive, and functional characteristics of recent-onset psychosis with autistic features: A 2-year longitudinal study Cognitive Behavioral Therapy for Insomnia in Pain Management for Nonspecific Chronic Spinal Pain: A Randomized Clinical Trial Multi-omics analysis reveals the impact of gut microbiota on antipsychotic-induced weight gain in schizophrenia A preliminary study of latent trajectories of change in dietary restraint during CBT-E for bulimia-spectrum eating disorders and their associations with treatment response Ketamine for catatonia: A novel treatment for an old clinical challenge? A systematic review of the evidence Lower plasma betaine levels in men at clinical high risk for psychosis: Findings from a metabolomics investigation Long-term outcome and fertility results of intraplacental choriocarcinoma: a retrospective study of 14 patients and literature review Common polygenic variation in the early medication change (EMC) cohort affects disorder risk, but not the antidepressant treatment response Associations between constipation risk and lifestyle, medication use, and affective symptoms in patients with schizophrenia: a multicenter cross-sectional study Associations between constipation risk and lifestyle, medication use, and affective symptoms in patients with schizophrenia: a multicenter cross-sectional study Long-term metabolic side effects of second-generation antipsychotics in Chinese patients with schizophrenia: A within-subject approach with modelling of dosage effects Exploring associations between trait symptoms and speech patterns in schizophrenia spectrum disorders: A mediation analysis Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression Assessing biomarkers of remission in female patients with anorexia nervosa (REMANO): a protocol for a prospective cohort study with a nested case-control study using clinical, neurocognitive, biological, genetic, epigenetic and neuroimaging… Assessing biomarkers of remission in female patients with anorexia nervosa (REMANO): a protocol for a prospective cohort study with a nested case-control study using clinical, neurocognitive, biological, genetic, epigenetic and neuroimaging… Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders Corrigendum to "Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study" [Schizophr. Res. volume 225 (May 2023) 173-181] Analysis of clinical studies on clozapine from 2012-2022 Schizophrenia interactome derived repurposable drugs and randomized control trials of two candidates Analysis of clinical studies on clozapine from 2012-2022 Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia Diffusion magnetic resonance imaging for treatment response prediction in schizophrenia spectrum disorders: A systematic review Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia Capacity to Consent in Healthcare: A Systematic Review and Meta-Analysis Comparing Patients with Bipolar Disorders and Schizophrenia Spectrum Disorders
Evidence Blueprint
Remission in schizophrenia spectrum disorders: A randomized trial of amisulpride, aripiprazole and olanzapine
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
Remission in schizophrenia spectrum disorders: A randomized trial of amisulpride, aripiprazole and olanzapine
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
Efficacy and safety of low-dose amisulpride versus olanzapine-fluoxetine combination in post-schizophrenic depression: A randomized controlled trial Symptomatic remission and recovery in major psychosis: Is there a role for BDNF? A secondary analysis of the LABSP cohort data Comparative Effectiveness of Amisulpride and Clozapine in the Treatment of Schizophrenia: A Systematic Review and Meta-Analysis Antipsychotic drugs in first-episode psychosis: A target trial emulation in the FEP-CAUSAL Collaboration Lower plasma tumor necrosis factor-alpha is associated with symptomatic remission in patients with schizophrenia Lower plasma tumor necrosis factor-alpha is associated with symptomatic remission in patients with schizophrenia A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort The Impact of Clozapine Delay on Clinical Outcomes in Schizophrenia Effect of olanzapine exposure on relapse and brain structure in patients with major depressive disorder with psychotic features Assessing Psychological Remission in Adolescent Anorexia Nervosa: A Comparison of Patient and Parent Report An evaluation of treatment response and remission definitions in adult obsessive-compulsive disorder: A systematic review and individual-patient data meta-analysis An evaluation of treatment response and remission definitions in adult obsessive-compulsive disorder: A systematic review and individual-patient data meta-analysis Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis Effectiveness and safety of second-generation antipsychotics for psychiatric disorders apart from schizophrenia: A systematic review and meta-analysis Behind the heterogeneity in the long-term course of first-episode psychosis: Different psychotic symptom trajectories are associated with different patterns of cannabis and stimulant use Short Term Psychodynamic Psychotherapy in addition to standard medical therapy increases clinical remission in Adolescents and Young Adults with Inflammatory Bowel Disease: a randomised controlled trial The association between symptomatic remission and social support in community-dwelling schizophrenia patients during COVID-19 The association between symptomatic remission and social support in community-dwelling schizophrenia patients during COVID-19 Treating child anxiety using family-based internet delivered cognitive behavior therapy with brief therapist guidance: A randomized controlled trial Predicting response to a smartphone-based cognitive-behavioral therapy for body dysmorphic disorder Effects of atypical antipsychotics on serum asprosin level and other metabolic parameters in patients with schizophrenia Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps Remission and Relapse Across Three Years in Pediatric Obsessive Compulsive Disorder Following Evidence-Based Treatments The Effect of Antipsychotics on Prolactinoma Growth: A Radiological and Serological Analysis Associations between alcohol use disorder polygenic score and remission in participants from high-risk families and Indiana biobank Gastrointestinal diagnoses in patients with eating disorders: A retrospective cohort study 2010-2020 Risk factors for abnormal glucose metabolism during antipsychotic treatment: A prospective cohort study Biomarker combination predicting imminent relapse after discontinuation of biological drugs in patients with rheumatoid arthritis in remission The effect of vortioxetine on anhedonia in patients with schizophrenia The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor Potential effect of antidepressants on remission from cocaine use disorder - A nationwide matched retrospective cohort study A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study Effects of antipsychotic drugs on energy metabolism Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease Factors influencing the effectiveness of digital cognitive behavioural therapy for chronic insomnia in clinical practice A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder Amisulpride as the antipsychotic of choice in severe psychotic disorder with comorbid impaired glucose tolerance Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression Sex differences in autonomic adverse effects related to antipsychotic treatment and associated hormone profiles Long-term remission rates and trajectory predictors in obsessive-compulsive disorder: Findings from a six-year naturalistic longitudinal cohort study Antipsychotic medication after a first episode of psychosis: taper or continue? Clinical Outcomes of Magnetic Seizure Therapy vs Electroconvulsive Therapy for Major Depressive Episode: A Randomized Clinical Trial Inflammatory blood cells and ratios at remission for psychosis relapse prediction: A three-year follow-up of a cohort of first episodes of schizophrenia Efficacy and Safety of Auricular Acupuncture for Depression: A Randomized Clinical Trial A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: A systematic review Serotonin 3 receptor antagonists for obsessive-compulsive disorder: A systematic review and pairwise meta-analysis Temporal trends in antipsychotic prescriptions for pediatric patients using an administrative hospital database in Japan: a retrospective study Safety outcomes of antipsychotics classes in drug-naïve patients with first-episode schizophrenia: A nationwide cohort study in South Korea Employment, education or training status (NEET) at baseline predicts high-threshold symptomatic remission in first episode psychosis: A cohort study An Intensive time series investigation of the relationships across eating disorder-specific fear responses and behavior urges in partially remitted anorexia nervosa Validation of the predictive value of BDNF -87 methylation for antidepressant treatment success in severely depressed patients-a randomized rater-blinded trial Dosage effects of psychodynamic and schema therapy in people with comorbid depression and personality disorder: four-arm pragmatic randomised controlled trial Intensive exposure treatment for obsessive compulsive disorder in old age. Comparative effectiveness of aripiprazole and olanzapine on neurocognitive profile of patients with schizophrenia Continuation or maintenance ECT for schizophrenia: A narrative review of case report data The Effectiveness of Adolescent-Focused Therapy and Family-Based Therapy for Anorexia Nervosa Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus Clinico-radiological parameters, biochemical and molecular alterations predicting remission and recurrence after surgical treatment of corticotroph adenomas - Cushing's disease Clinico-radiological parameters, biochemical and molecular alterations predicting remission and recurrence after surgical treatment of corticotroph adenomas - Cushing's disease Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol Treatments for partial remission of major depressive disorder: a systematic review and meta-analysis Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults Inpatient antipsychotic medication switching and rehospitalization risk among patients with schizophrenia-spectrum disorders